logo
Share SHARE
FONT-SIZE Plus   Neg

FDA Approves J&J' New Diabetes Drug INVOKANA Or Canagliflozin

Johnson & Johnson (JNJ: Quote) company Janssen Pharmaceuticals, Inc. announced the U.S. FDA approval for INVOKANA or canagliflozin tablets for the treatment of adults with type 2 diabetes. INVOKANA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

According to the FDA, Type 2 diabetes is the most common form of the disease, affecting about 24 million people and accounting for more than 90 percent of diabetes cases diagnosed in the U.S.

"Invokana is the first diabetes treatment approved in a new class of drugs known as sodium-glucose co-transporter 2 (SGLT2) inhibitors," said Mary Parks, M.D., director of the Division of Metabolism and Endocrinology Products in the FDA's Center for Drug Evaluation and Research.

Janssen noted that the global Phase 3 clinical program, which enrolled 10,285 patients in nine studies, showed that the 100 mg and the 300 mg doses of INVOKANA improved glycemic control and, in prespecified secondary endpoints, were associated with significant reductions in body weight and systolic blood pressure.

Invokana works by blocking the reabsorption of glucose by the kidney, increasing glucose excretion, and lowering blood glucose levels in diabetics who have elevated blood glucose levels.

Jimmy Ren, Ph.D., Therapeutic Area Lead, Metabolics, Medical Affairs, Janssen Pharmaceuticals, Inc., stated, "INVOKANA provides patients with type 2 diabetes the option of a once-daily oral therapy that offers improved glycemic control and, in Phase 3 studies, showed an incidence of hypoglycemia - low blood glucose - that was lower than with glimepiride and similar to that of sitagliptin,"

The FDA specified that the most common side effects of Invokana are vaginal yeast infection (vulvovaginal candidiasis) and urinary tract infection.

Janssen plans to partner with other Johnson & Johnson companies focused on diabetes to bring the product to healthcare professionals treating patients with diabetes.

JNJ closed Thursday's regular trading session at $81.53.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Social game developer Zynga Inc. said Wednesday after the markets closed that its first quarter loss narrowed from last year, as revenue increased and costs and expenses fell. The company's quarterly adjusted loss per share was also narrower than analysts estimated and its quarterly revenue beat analysts' forecast. Twenty-First Century Fox reported a better-than-expected third-quarter profit, on growth at its cable and film entertainment business, partly offset by the absence of Super Bowl as well as currency headwinds. Activision Blizzard Inc. (ATVI) on Wednesday reported a surge in profit for the first quarter, as revenues increased reflecting strong growth in digital business with the video game publisher's profit and revenues topping Wall Street estimates. Moving ahead, the company detailed a weak outlook for...
comments powered by Disqus
RELATED NEWS
Trade JNJ now with 
Follow RTT